REG - Venture Life Group - Total Voting Rights

Venture LifeAnnouncement

01/12/2025 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251201:nRSA7523Ja&default-theme=true

RNS Number : 7523J  Venture Life Group PLC  01 December 2025

1 December 2025

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Company")

 

Total Voting Rights

 

In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1,
the Company announces that on 30 November 2025 it had the following ordinary
shares of 0.3 pence each in the capital of the Company:

 

 Total Issued Share Capital  128,052,312

 Shares held in Treasury     376,318

 Total Voting Rights         127,675,994

 

Each Ordinary Share in issue carries one vote while Ordinary Shares held in
Treasury have no voting rights.

 

Accordingly, the total number of voting rights above may be used by
shareholders as the denominator for the calculation by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the FCA's Disclosure
and Transparency Rules.

 

 

For further information, please contact:

Venture Life Group
PLC
                +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cavendish Capital Markets Limited (Nomad and
Broker)
           +44 (0) 20 7720 0500

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRMZMGZVMMGKZM



            Copyright 2019 Regulatory News Service, all rights reserved